Gregg W. Stone MD

@GreggWStone · New York and the world · joined 24 Dec 2016

Interventional cardiologist, trialist, innovator, educator, husband, father, loyal friend

30 809Followers

751Following

5 355Posts total

48.4KViews on collected posts

Последние посты

Gregg W. Stone MD@GreggWStone30 Aug

@GreggWStone Solid results. But let's be real, 25 centers in China and zero here. We're falling behind on exactly this kind of clinical research. 1.2K views · 6 likes · 0 reposts · 0 replies Open on X →

Gregg W. Stone MD@GreggWStone30 Aug

Results were consistent in HFrEF and HFpEF & IpcPH and CpcPH. PADN also → concordant improvements in KCCQ, NT-pro-BNP, 6MWD and left and right heart structure/function. PADN in group 2 PH is further being studied in the sham-controlled PULSE-LHD RCT in CpcPH (NCT07214376). https:

2.3K views · 13 likes · 6 reposts · 2 replies Open on X →

Gregg W. Stone MD@GreggWStone30 Aug

The primary EP of clinical worsening (death, transplant, HF hosp, outpt HF or 6MWD↓) was reduced by 51% with PADN (51.5% vs 25.7%, HR 0.49, 95%CI 0.30-0.82, p=0.006). Clinical events w/o the 6MWD component were also ↓52% by PADN (20.8% vs 40.3%, HR 0.48 (0.27–0.86), P=0.01). http

4.1K views · 23 likes · 6 reposts · 1 replies Open on X →

Gregg W. Stone MD@GreggWStone30 Aug

Presented today and published in NEJM, our PADN-HF-PH trial in which 264 pts with left-heart failure (HFrEF or HFpEF) and pulmonary hypertension (mPAP >20 mmHg and PCWP >15 mmHg) were randomized at 25 centers to pulmonary artery denervation (PADN) + GDMT vs GDMT alone. https://t.

23K views · 175 likes · 51 reposts · 4 replies Open on X →

Gregg W. Stone MD@GreggWStone28 Aug

@GreggWStone Yo siempre uso biva en primaria 233 views · 1 likes · 0 reposts · 0 replies Open on X →

Gregg W. Stone MD@GreggWStone28 Aug

In their editorial Valgimigli et al note the class IA 2025 ACC/AHA GL for bival to ↓ death and bleeding in primary PCI and conclude “The present analysis supports the broader use of bivalirudin which should represent the mainstay anticoagulant in primary PCI rather than UFH.” 728 views · 3 likes · 0 reposts · 1 replies Open on X →

Gregg W. Stone MD@GreggWStone28 Aug

Bivalirudin is generic and does not cost much more than UFH. This simple switch (even if UFH was given in the ER) in all PCI-STEMI pts (low and high bleeding-risk) will save tens of thousands of lives each year and reduce major bleeding, even with radial access (as in BRIGHT-4). 407 views · 2 likes · 0 reposts · 2 replies Open on X →

Gregg W. Stone MD@GreggWStone28 Aug

76% of patients were low-risk for bleeding. 30-day death was reduced with bival from 2.6% to 1.4% in low bleeding-risk pts (Δ1.2%) and from 8.3% to 7.8% (Δ0.5%) in high bleeding-risk pts. So most lives were saved by treating low bleeding-risk pts! 845 views · 4 likes · 0 reposts · 1 replies Open on X →

Gregg W. Stone MD@GreggWStone4 Aug

Our publ in JACC CV Imaging from ILUMIEN IV: Pre-PCI OCT stratifies 2-year TVF based on plaque morphology. Highest risk (mainly due to TVR) were calcific > lipidic > fibrotic lsns, related to stent under-expansion. Despite median calc arc 271°, only 26% had advanced lesion prep.

6.4K views · 56 likes · 14 reposts · 5 replies Open on X →

Gregg W. Stone MD@GreggWStone4 Aug

Our publ in CIrc HF from RELIEVE-HF. Although group outcomes with V-wave atrial shunt implant were markedly positive in HFrEF and negative in HFrEF, individual pt modeling predicts 67.2% and 21.4% HFrEF and HFpEF pts might benefit. Download free: https://t.co/BoxrCmpadc https://

5.1K views · 42 likes · 7 reposts · 4 replies Open on X →

Gregg W. Stone MD@GreggWStone1 Aug

Our AHJ publ, lessons from the feasibility phase of the PCORI-funded RECHARGE trial of PCI v CABG in women, Black & Hispanic pts with a novel pt-centered endpoint of survival & QOL. They said it couldn’t be done – it can! - with dedicated focus on enrolling under-represented pts.

4.2K views · 32 likes · 4 reposts · 3 replies Open on X →

На фоне аккаунтов своего размера

11 постов за последние 90 дней рядом с диапазоном 10K–100K подписчиков. показывается широко, но откликается мало кто.

Медианные просмотры2 256этот аккаунт924медиана для 10K–100K

Охват, %7.32%этот аккаунт3.62%медиана для 10K–100K

Вовлечённость, %0.92%этот аккаунт1.52%медиана для 10K–100K

Показатель	Этот аккаунт	Медиана для 10K–100K	Отношение
Медианные просмотры на пост	2 256	924	2.44×
Охват (просмотры ÷ подписчики)	7.32%	3.62%	2.02×
Вовлечённость	0.92%	1.52%	0.61×

Другие в этом диапазоне → Сравнить с другим аккаунтом → Как считаются эти ориентиры →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

4.2K1 Aug

5.1K4 Aug

6.4K

84528 Aug

407

728

233

23K30 Aug

4.1K

2.3K

1.2K

Last 11 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.92%1 Aug

1.03%4 Aug

1.17%

0.59%28 Aug

0.98%

0.55%

0.43%

1.01%30 Aug

0.79%

0.93%

0.52%

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.52%.

What the audience does

Likes60.5%357 in total

Reposts14.9%88 in total

Replies3.9%23 in total

Quotes0.7%4 in total

Bookmarks20.0%118 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Последние посты

На фоне аккаунтов своего размера

Growth & engagement

Views per post

Engagement rate per post

What the audience does

Похожие аккаунты